Compare Incyte Corporation (INCY) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Jabil Inc — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Jabil Inc trades at $319 (market cap $32.06B). The key difference: Jabil Inc is the larger of the two by market cap, and Jabil Inc pays a 0.1% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | JBL | |
|---|---|---|
Market Cap | $23.11B | $32.06B |
Sector | Health | Technology |
52-Week High | $118.52 | $385.50 |
52-Week Low | $67.38 | $192.49 |
Enterprise Value | $19.13B | $34.59B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
JBL trades at $305.91, up 1.63% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 50% analyst buy ratings and a $448.29 consensus price target, representing 46% upside potential. Recent news highlights AI infrastructure growth and new logistics hub expansion in Penang, while technical indicators show oversold conditions with RSI at 17.67.
The outlook remains positive with AI-driven revenue growth accelerating, though valuation at 38.29 P/E appears stretched. Key risks include competitive pressures in EMS sector and execution challenges in scaling AI manufacturing capacity. The stock offers growth exposure to AI infrastructure boom but requires monitoring of margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
